Speculation: The widespread use of antibacterial electrospun nanofibers is usually restricted resulting from their low loading capability to hold antibiotics and the necessity to use poisonous natural solvents to spice up the antibiotic loading capability. Nanofibers based mostly on pure excipients, corresponding to cyclodextrin (CD)-based nanofibers, can carry bigger quantities of antibiotics whereas reaching higher stability by way of inclusion complexation.
Experiments: Nanofibers have been produced by electrospinning and analyzed by electron microscopy to analyze the morphology of fibers. The formation of inclusion-complexation was analyzed by 1H NMR, FTIR, and XRD. Thermal evaluation of the fibers was carried out utilizing TGA. Ab initio modeling research have been carried out to calculate the complexation energies of antibiotics with CD. A disk-diffusion assay was used to take a look at the antibacterial exercise of the fibers.
Findings: Bead-free antibacterial nanofibers with imply diameters between 340 and 550 nm have been produced. The formation of inclusion complexes (IC) between the CD and the antibiotics was confirmed by FTIR and 1H NMR, which was additional verified by the disappearance of the crystalline peaks of antibiotics as decided by XRD evaluation. Thermal evaluation of the nanofibers revealed that the formulations confirmed good antibiotic encapsulation (45-90%). Ab initio simulations revealed that gentamicin had the very best complexation vitality, adopted by kanamycin, chloramphenicol, and ampicillin. The antibacterial nanofibers quickly dissolved in water and synthetic saliva, efficiently releasing the CD antibiotic complexes. The nanofibers confirmed excessive antibacterial exercise towards Gram-negative Escherichia coli.
Challenges in recruitment and adherence to a randomized scientific trial in Brazil on the results of transcutaneous nervous electrical stimulation on people with peripheral arterial illness: A feasibility examine
Goal: Describe the feasibility, boundaries through the recruitment and intervention interval, recruitment charge (success and effectivity), and the extent of participation and adherence within the randomized scientific trial to confirm the results of transcutaneous electrical nerve stimulation (TENS) for the signs of intermittent claudication (IC) and its repercussions on practical capability, cardiorespiratory health and cardiovascular autonomic operate in people with sta II Fontaine classification, residing in Brazil.
Design: Potential, double-blind, randomized scientific trial.
Setting: Stage secondary.
Contributors: A complete of 63 individuals have been screened, of which 12.6% have been included. Eight people with peripheral arterial illness (PAD) and IC underwent a protocol that lasted Eight weeks.
Interventions: The experimental group acquired 45 minutes TENS 10 Hz, adopted by 30 minutes of cardio train, and the management group acquired a placebo TENS additionally adopted by 30 minutes of train. Incremental strolling take a look at, gait impairment questionnaire, treadmill take a look at, coronary heart charge variability, and 4-second take a look at have been utilized, contemplating adherence, success, and effectivity.
Outcomes: Probably the most environment friendly recruitment sources have been as follows: 1) referral by doctor and a couple of) referral by a physiotherapist. Out of 63 individuals, 8 (12.6%) have been included within the scientific trial. Contributors have been excluded as a result of following causes: not assembly the standards (41 individuals (65%)), locomotion (6 individuals (9.5%)), transportation (5 individuals (7.9%)), work launch (1 participant (1.6%)), and curiosity (2 individuals (3.2%)). The general participation was 99 individuals (51.6%) in a complete of 192 classes supplied.
Conclusion: It was not doable to achieve recruitment and adherence charges. The outcomes of this scientific trial reinforce that PAD is uncared for, and methods together with a multidisciplinary strategy with the efficient participation of nursing, physiotherapy, drugs, and diet professionals, are essential to optimize care for people with PAD must be strengthened. Brazilian Registry of Scientific Trials (RBR-8RTZFN).

Fast-dissolving antibacterial nanofibers of cyclodextrin/antibiotic inclusion complexes for oral drug delivery
Immunomodulatory Exercise of the Marine Sponge, Haliclona ( Soestella) sp. (Haplosclerida: Chalinidae), from Sri Lanka in Wistar Albino Rats: Immunosuppression and Th1-Skewed Cytokine Response
Pure secondary metabolites of sponges of the genus Haliclona are related to an array of organic exercise with therapeutic utilization. We investigated the immunopharmacological properties of a presumably novel marine sponge species from Sri Lanka, Haliclona (Soestella) sp. Sponge materials was collected from southern Sri Lanka by scuba diving. Sponge identification was based mostly on spicule and skeleton morphology utilizing mild microscopy. Chosen in vivo and ex vivo checks investigated nonfunctional and practical immunomodulatory exercise of the Haliclona (Soestella) sp. crude extract (HSCE) within the Wistar rat mannequin.
In comparison with the controls, rats orally gavaged day by day for 14 consecutive days with 15 mg/kg dose of the HSCE manifested a big discount of immune cell counts of whole WBCs, lymphocytes (38%), platelets, splenocytes (20%), and bone marrow cells (BMC; 60%) (p < 0.001), with a concurrent enhance within the neutrophil : lymphocyte ratio (p < 0.05); RBC counts abated by 53. A major discount of the splenosomatic index was evident with the 10 and 15 mg/kg doses (p < 0.001). Rat plasma TNF-α cytokine stage was augmented by tenfold (p < 0.001), IL-6 stage by twofold (p < 0.01) with the 15 mg/kg HSCE remedy, whereas IL-10 was detectable in rat plasma solely with this remedy; the corresponding Th1 : Th2 cytokine ratio (TNF-α : IL-10) was indicative of an unequivocal Th1-skewed cytokine response (p < 0.01).
mPEG-SH,500 |
33-MF001003-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
mPEG-COOH?500 |
33-MF001017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
mPEG-MAL,500 |
33-MF001022-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
HO-PEG-COOH,500 |
33-HE002017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
SH-PEG-COOH,500 |
33-HE003017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
HS-PEG-NHS,500 |
33-HE003023-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
NH2-PEG-COOH,500 |
33-HE005017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
N3-PEG-OH,500 |
33-HE006002-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
N3-PEG-BIOTIN,500 |
33-HE006041-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
Biotin-PEG-COOH,500 |
33-HE041017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
SH-PEG-SH,500 |
33-HO003003-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
AlKyne-PEG-AlKyne,500 |
33-HO007007-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
COOH-PEG-COOH,500 |
33-HO017017-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
SC-PEG-SC,500 |
33-HO023023-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
MC Cellufine S-500 |
21-200-51 |
JNC America |
5 x 1 ml |
EUR 286.8 |
MC Cellufine S-500 |
21-200-55 |
JNC America |
5 x 5 ml |
EUR 504 |
MC Cellufine C-500 |
19-800-51 |
JNC America |
5 x 1 ml |
EUR 260.4 |
MC Cellufine C-500 |
19-800-55 |
JNC America |
5 x 5 ml |
EUR 414 |
MC Cellufine Q-500 |
19-907-51 |
JNC America |
5 x 1 ml |
EUR 260.4 |
MC Cellufine Q-500 |
19-907-55 |
JNC America |
5 x 5 ml |
EUR 414 |
Cellufine A-500 |
675980335 |
JNC America |
10 lt |
Ask for price |
MC Cellufine A-200 |
19-611-51 |
JNC America |
5 x 1 ml |
EUR 260.4 |
MC Cellufine A-800 |
19-865-51 |
JNC America |
5 x 1 ml |
EUR 260.4 |
MC Cellufine A-800 |
19-865-55 |
JNC America |
5 x 5 ml |
EUR 414 |
5-Methylcytosine (5-mC) Monoclonal Antibody [33D3] |
A-1014 |
EpiGentek |
-
EUR 721.20
-
EUR 82.50
-
EUR 239.80
-
EUR 456.50
|
- 100 µg
- 10 ug
- 50 ug
- 100 ug
|
MC Cellufine MAX AminoButyl |
21-500-15 |
JNC America |
1 x 5 ml |
EUR 541.2 |
MC Cellufine MAX AminoButyl |
21-500-51 |
JNC America |
5 x 1 ml |
EUR 541.2 |
SH-PEG-NH2,500 |
33-HE003005-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
MAL-PEG-NH2,500 |
33-HE022005-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
NH2-PEG-NH2,500 |
33-HO005005-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
N3-PEG-N3,500 |
33-HO006006-500 |
Biochempeg |
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
MC Cellufine MAX Q-r |
20-500-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Q-r |
20-500-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine Sulfate |
19-845-15 |
JNC America |
1 x 5 ml |
EUR 439.2 |
MC Cellufine Sulfate |
19-845-51 |
JNC America |
5 x 1 ml |
EUR 439.2 |
MC Cellufine Phosphate |
195-15 |
JNC America |
1 x 5 ml |
EUR 516 |
MC Cellufine Phosphate |
195-51 |
JNC America |
5 x 1 ml |
EUR 516 |
Cellufine Q-500 |
675982335 |
JNC America |
10 lt |
Ask for price |
Cellufine C-500 |
675983335 |
JNC America |
10 lt |
Ask for price |
MC Cellufine MAX DEAE |
21-000-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX DEAE |
21-000-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX Butyl |
21-100-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Butyl |
21-100-55 |
JNC America |
5 x 5 ml |
EUR 644.4 |
MC Cellufine MAX GS |
21-300-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX GS |
21-300-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX IB |
21-600-15 |
JNC America |
1 x 5 ml |
EUR 362.4 |
MC Cellufine MAX IB |
21-600-51 |
JNC America |
5 x 1 ml |
EUR 362.4 |
MC Cellufine SPA-HC |
21-900-11 |
JNC America |
1 x 1 ml |
EUR 446.4 |
MC Cellufine SPA-HC |
21-900-15 |
JNC America |
1 x 5 ml |
EUR 663.6 |
MC Cellufine SPA-HC |
21-900-51 |
JNC America |
5 x 1 ml |
EUR 663.6 |
MC Cellufine MAX Phenyl |
20-700-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Phenyl |
20-700-55 |
JNC America |
5 x 5 ml |
EUR 644.4 |
MC Cellufine MAX CM |
20-900 |
JNC America |
100 ml |
EUR 458.4 |
MC Cellufine MAX CM |
20-900-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX CM |
20-900-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX CM |
20-901 |
JNC America |
500 ml |
EUR 1756.8 |
MC Cellufine MAX CM |
20-902 |
JNC America |
5 lt |
Ask for price |
MC Cellufine MAX CM |
20-903 |
JNC America |
10 lt |
Ask for price |
MC Cellufine Etclean L |
200-15 |
JNC America |
1 x 5 ml |
EUR 427.2 |
MC Cellufine Etclean L |
200-51 |
JNC America |
5 x 1 ml |
EUR 427.2 |
MC Cellufine GH-25 |
19-711-55 |
JNC America |
5 x 5 ml |
EUR 516 |
MC Cellufine Etclean S |
201-15 |
JNC America |
1 x 5 ml |
EUR 427.2 |
MC Cellufine Etclean S |
201-51 |
JNC America |
5 x 1 ml |
EUR 427.2 |
MC Cellufine MAX DexS-Vir |
21-800-15 |
JNC America |
1 x 5 ml |
EUR 362.4 |
MC Cellufine MAX DexS-Vir |
21-800-51 |
JNC America |
5 x 1 ml |
EUR 362.4 |
MC Cellufine MAX S-r |
20-300-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX S-h |
20-400-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX S-h |
20-400-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX Q-h |
20-600-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Q-h |
20-600-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
MC Cellufine MAX Phenyl LS |
20-800-51 |
JNC America |
5 x 1 ml |
EUR 325.2 |
MC Cellufine MAX Phenyl LS |
20-800-55 |
JNC America |
5 x 5 ml |
EUR 644.4 |
MC Cellufine MAX S-r |
20300-55 |
JNC America |
5 x 5 ml |
EUR 631.2 |
Cellufine A-800 |
673980335 |
JNC America |
10 lt |
Ask for price |
Cellufine A-200 |
676-980-327 |
JNC America |
100 ml |
EUR 388.8 |
Cellufine A-200 |
676980335 |
JNC America |
10 lt |
Ask for price |
MBD1 Polyclonal Antibody |
A-1006 |
EpiGentek |
-
EUR 740.34
-
EUR 117.70
-
EUR 306.90
-
EUR 462.00
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
5-Hydroxymethylcytosine (5-hmC) Monoclonal Antibody [HMC/4D9] |
A-1018 |
EpiGentek |
-
EUR 702.06
-
EUR 82.50
-
EUR 239.80
-
EUR 443.30
|
- 100 µg
- 10 ug
- 50 ug
- 100 ug
|
PRDM4 Polyclonal Antibody |
A-2004 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM5 Polyclonal Antibody |
A-2005 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM10 Polyclonal Antibody |
A-2010 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM11 Polyclonal Antibody |
A-2011 |
EpiGentek |
-
EUR 754.26
-
Ask for price
-
Ask for price
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM13 Polyclonal Antibody |
A-2013 |
EpiGentek |
-
EUR 754.26
-
Ask for price
-
Ask for price
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM16 Polyclonal Antibody |
A-2016 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PRDM17 Polyclonal Antibody |
A-2017 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
EZH1 Polyclonal Antibody |
A-2018 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
HSF1 Polyclonal Antibody |
A-2401 |
EpiGentek |
-
EUR 905.64
-
EUR 235.40
-
EUR 423.50
-
EUR 574.20
|
- 200 µl
- 50 ul
- 100 ul
- 200 ul
|
PRMT3 Polyclonal Antibody |
A-3003 |
EpiGentek |
-
EUR 740.34
-
Ask for price
-
Ask for price
-
EUR 462.00
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
SET1 Polyclonal Antibody |
A-3011 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
SET07 Polyclonal Antibody |
A-3013 |
EpiGentek |
-
EUR 754.26
-
Ask for price
-
Ask for price
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
LSD1 Polyclonal Antibody |
A-3018 |
EpiGentek |
-
EUR 754.26
-
EUR 117.70
-
EUR 284.90
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
HDAC10 Polyclonal Antibody |
A-4010 |
EpiGentek |
-
EUR 754.26
-
Ask for price
-
Ask for price
-
EUR 470.80
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PCAF Polyclonal Antibody |
A-4012 |
EpiGentek |
-
EUR 740.34
-
EUR 117.70
-
EUR 306.90
-
EUR 462.00
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
Histone H3K9ac (Acetyl H3K9) Polyclonal Antibody |
A-4022 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K14ac (Acetyl H3K14) Polyclonal Antibody |
A-4023 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K18ac (Acetyl H3K18) Polyclonal Antibody |
A-4024 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K23ac (Acetyl H3K23) Polyclonal Antibody |
A-4025 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 383.90
|
|
Histone H3K56ac (Acetyl H3K56) Polyclonal Antibody |
A-4026 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K4me1 (H3K4 Monomethyl) Polyclonal Antibody |
A-4031 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K4me2 (H3K4 Dimethyl) Polyclonal Antibody |
A-4032 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 383.90
|
|
Histone H3K4me3 (H3K4 Trimethyl) Polyclonal Antibody |
A-4033 |
EpiGentek |
-
EUR 555.90
-
EUR 177.10
-
EUR 342.10
-
EUR 479.60
|
|
Histone H3K9me1 (H3K9 Monomethyl) Polyclonal Antibody |
A-4034 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K9me2 (H3K9 Dimethyl) Polyclonal Antibody |
A-4035 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K9me3 (H3K9 Trimethyl) Polyclonal Antibody |
A-4036 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K27me1 (H3K27 Monomethyl) Polyclonal Antibody |
A-4037 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K27me2 (H3K27 Dimethyl) Polyclonal Antibody |
A-4038 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K27me3 (H3K27 Trimethyl) Polyclonal Antibody |
A-4039 |
EpiGentek |
-
EUR 555.90
-
EUR 177.10
-
EUR 342.10
-
EUR 479.60
|
|
Histone H3K36me1 (H3K36 Monomethyl) Polyclonal Antibody |
A-4040 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K36me2 (H3K36 Dimethyl) Polyclonal Antibody |
A-4041 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K36me3 (H3K36 Trimethyl) Polyclonal Antibody |
A-4042 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K79me1 (H3K79 Monomethyl) Polyclonal Antibody |
A-4043 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K79me2 (H3K79 Dimethyl) Polyclonal Antibody |
A-4044 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H3K79me3 (H3K79 Trimethyl) Polyclonal Antibody |
A-4045 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H4K20me1 (H4K20 Monomethyl) Polyclonal Antibody |
A-4046 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H4K20me2 (H4K20 Dimethyl) Polyclonal Antibody |
A-4047 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 336.60
-
EUR 470.80
|
|
Histone H4K20me3 (H4K20 Trimethyl) Polyclonal Antibody |
A-4048 |
EpiGentek |
-
EUR 555.90
-
EUR 173.80
-
EUR 302.50
-
EUR 470.80
|
|
Histone H3K27ac (Acetyl H3K27) Polyclonal Antibody |
A-4708 |
EpiGentek |
-
EUR 813.42
-
EUR 173.80
-
EUR 299.20
-
EUR 510.40
|
- 100 µl
- 25 ul
- 50 ul
- 100 ul
|
CRISPR Cas9 Monoclonal Antibody [7A9] |
A-9000 |
EpiGentek |
-
EUR 573.30
-
EUR 71.50
-
EUR 200.20
-
EUR 355.30
|
- 100 µg
- 10 ug
- 50 ug
- 100 ug
|
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
A-9001 |
EpiGentek |
-
EUR 559.38
-
EUR 70.40
-
EUR 192.50
-
EUR 338.80
|
- 100 µg
- 10 ug
- 50 ug
- 100 ug
|
CLIMP-63 Polyclonal Antibody |
A-0701 |
EpiGentek |
-
EUR 754.26
-
EUR 290.40
-
EUR 470.80
|
|
DNMT3A Polyclonal Antibody |
A-1003 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
DNMT3B Polyclonal Antibody |
A-1004 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
DNMT3L Polyclonal Antibody |
A-1005 |
EpiGentek |
-
EUR 740.34
-
EUR 235.40
-
EUR 462.00
|
|
Ex vivo bone marrow cell and splenocyte proliferation have been considerably and dose dependently impaired by HSCE (IC50 0.719 and 0.931 μg/mL, respectively; p < 0.05). Subacute toxicity testing established that HSCE was devoid of basic poisonous, hepatotoxic, and nephrotoxic results. In conclusion, HSCE was orally lively, unhazardous, and successfully suppressed nonfunctional and practical immunological parameters of Wistar rats, suggestive of the potential use of the HSCE as an immunosuppressant drug lead.